Value assessment on anti-cancer drugs hotly discussed

24 October 2019 - Experts are raising the need to establish tools to calculate the value of new anticancer medicines ...

Read more →

Sanofi to cover part of Dupixent cost for atopic dermatitis patients

11 October 2019 - Sanofi said it would run a program to support part of the cost of Dupixent, a ...

Read more →

CDK4/6 inhibitor+fulvestrant combo nears getting benefit

2 October 2019 - The combination therapy of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor and fulvestrant for advanced or metastatic ...

Read more →

'Xtandi emerges as convenient treatment option for prostate cancer patients'

25 September 2019 - Astellas Korea is strengthening its position in the local prostate cancer market with Xtandi, a hormone therapy ...

Read more →

Lenvima to get benefit as first-line treatment of hepatocellular carcinoma

16 September 2019 - Lenvima (lenvatinib), a new liver cancer drug that arrived in a decade after Nexavar (sorafenib), is to ...

Read more →

Pharmacists demand audit over Gliatilin’s insurance benefit

27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...

Read more →

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anaemia

 1 August 2019 - Novartis Korea’s Revolade (eltrombopag olamine) will receive reimbursement for treating people with severe aplastic anaemia who ...

Read more →

Takeda’s Zejula poised to change local ovarian cancer treatment market

29 July 2019 - Takeda’s Zejula (ingredient: niraparib) became eligible for an insurance benefit, according to the Health Insurance Review and ...

Read more →

Pfizer's Besponsa, Takeda's Zejula likely to get insurance coverage

26 July 2019 - Pfizer's Besponsa, a B-cell lymphoblastic leukaemia treatment, and Takeda's Zejula, an ovarian cancer treatment, have passed ...

Read more →

Two cancer immunotherapy makers face different situations in reimbursement talks

18 July 2019 - MSD returns to renegotiation table; BMS suffers from partner’s silence. ...

Read more →

Eli Lilly Korea gains further reimbursement for psoriasis treatment Taltz

1 July 2019 - The Korean branch of Eli Lilly said that it had gained additional reimbursement for its psoriasis ...

Read more →

Delayed patient access to innovative medical technologies in South Korea: a lead-time analysis of reimbursement coverage determinations

20 June 2019 - Timely access to innovative medical technologies driven by accelerated patient access pathways can substantially improve the health ...

Read more →

Role of health technology assessment in drug policies: Korea

13 June 2019 - South Korea is the first Asian country to mandate the submission of pharmacoeconomic data for reimbursement decision ...

Read more →

Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific Region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea

13 June 2019 - Medicine price directly affects affordability and access to medicines particularly in countries where a major portion of ...

Read more →

Atopic dermatitis patients demand reimbursement for Sanofi’s biological drug

12 June 2019 - Korean patients with severe atopic dermatitis gathered in front of the National Assembly on Tuesday to ...

Read more →